MISOPROST is Abortifacient drug in Egypt-EN

MISOPROST: Abortifacient drug in Egypt Misoprost Composition Each tablet contains: 200 mcg Misoprostol.

Misoprost Properties Misoprostol is a synthetic analogue of alprostadil (prostaglandin E which is used in the prophylaxis and treatment of peptic ulcers, particularly those induced by non-steroidal inflammatory drugs (NSAIDS).

Following oral administration, Misoprost (Misoprostol) is rapidly absorbed and metabolized to its active form.

Misoprost (Misoprostol) has both anti- secretory (inhibiting gastric acid secretion) and mucosal protective properties.

NSAIDS inhibit the synthesis of prostaglandin. the deficiency of which within the gastric mucosa may lead to diminishing bicarbonate and mucus secretion and may contribute to mucosal damage.

In addition to its anti-secretory activity, Misoprost can increase bicarbonate and mucus production.

Misoprost Indications Misoprost (Misoprostol) is indicated for the prevention of NSAIDS (non-steroidal anti-inflammatory drugs, including aspirin)- induced gastric ulcers in patients at high risk of complications from gastric ulcer, eg, the elderly and patients with concomitant debilitating disease, as well as patients at high risk of developing gastric ulceration, such as patients with a history of ulcer, It has not been shown to prevent duodenal ulcers in patients taking NSAIDS. It should be taken for the duration of NSAID therapy.

It has been shown to prevent gastric ulcers in controlled studies of three months' duration.

It had no effect, compared to placebo, on gastro-intestinal pain or discomfort associated with NSAIDS use.

Misoprost Contraindications  

Allergy to prosraglandins.

Pregnancy.

Misoprost Side Effects Diarrhea, abdominal pain. flatulance, dyspepsia, nausea, vomiting, skin rashes, headache, constipation.

Gynecological disorders include spotting, cramps, menestrual disorder, hypermenorrhea, dysmenorrhea, Post-menopausal vaginal bleeding.

Precautions and warnings Misoprost should not be given to patients who are pregnant or who may become pregnant because of its abortifacient property.

Misoprost is not excreted in human milk since it is rapidly metabolized throughout the body. However, it is not known if the active metabolite is excreted in human milk. As such Misoprost should not be administered to nursing mothers because the potential excretion of active metabolite could cause significant diarrhea in nursing infants.

Dosage and administration The recommended adult oral dose of Misoprost for the prevention of NSAIDS - induced gastric ulcers is 200 mcg four rimes daily for the duration of NSAID therapy.

Misoprost should be taken with a meal, and the last dose of the day should be at bedtime. If the 200 mcg dose cannot be tolerated, a dose of 100 mcg can be used.

Extra information   

Store at room temperature a way from light and humidity.

Carton box containing two PVC / AI. strips of 10 tablets each with inner pamphlet.

Misoprost manufactured by Chemical Industries Development (CID) For Multipharma Co.



For more information, inquiries, and product request Whatsapp us: 00201061282386.

 

AR- patient information leaflet- click here.

EN- patient information leaflet- click here.